東華大學圖書館 |

Gut Microbiota as Potential Non-Invasive Biomarker for Kidney Graft Rejection /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Gut Microbiota as Potential Non-Invasive Biomarker for Kidney Graft Rejection // Vanessa Visconti.
作者:	Visconti, Vanessa,
面頁冊數:	1 electronic resource (112 pages)
附註:	Source: Dissertations Abstracts International, Volume: 86-04, Section: B.
Contained By:	Dissertations Abstracts International86-04B.
標題:	Cancer. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31604796
ISBN:	9798342141871

Gut Microbiota as Potential Non-Invasive Biomarker for Kidney Graft Rejection /
Visconti, Vanessa,

Gut Microbiota as Potential Non-Invasive Biomarker for Kidney Graft Rejection /Vanessa Visconti. - 1 electronic resource (112 pages)

Source: Dissertations Abstracts International, Volume: 86-04, Section: B.

Background:Kidney graft rejection still represents the major cause of graft loss in kidney transplant recipients. Increasing evidences have demonstrated the link between gut microbiota alterations and allograft outcome, mostly attributable to the bidirectional relationship between gut microbiome and systemic immune system activation's profile. Purpose of this study was to characterize the gut microbiota of kidney transplant recipients with and without allograft rejection (AR) in order to identify a specific microbial fingerprint associated with rejection. We also aimed to define a bacterial genomic biomarker for rejection, which characterisation could lead to the etablishment of a non-invasive method for the diagnosis of AR, thus preventing patient's exposure to possible complications related to renal graft biopsy. Furthermore, we intented to perform a predictional functional analysis in order to hipotetise functional implications of the different microbial compositions between the two groups.Methods:We enrolled a total of 76 patients, of which 66 were suitable for completing the clinical trial. Into this prospective cohort trial involving adult kidney transplant recipients with and without AR, fecal bacterial composition was characterized using 16S rRNA gene sequencing of the V4 hypervariable region, and taxonomy was assigned after amplicon sequence variants (ASV) clustering.Results:Gut microbial composition of recipients with AR was characterised by lower richness, especially pronounced when comparing alpha diversity metrics of patients with cronic active T cellular mediated rejection to controls (Chao1 index p-value= 0.025 and ACE index p-value= 0.02). PERMANOVA analysis based on Aitchison distance, Bray-Curtis dissimilarity and Jaccard distance revealed differences in the microbial beta-diversity between controls and patients with AR with an adjusted p-value respectively of p = 0.01, p=0.021 and p= 0.022. Use of proton pump inhibitors did not significantly influenced the gut microbial composition of the cohorts. We identified a gut microbial fingerprint for each of our study cohorts, where the control group was characterised by a significant enrichment of anti-inflammatory taxa, while the rejection group by bacteria well known for their role in chronic inflammation. We also identified group-specific ASVs able to distinguish patients with AR from controls as non-invasive biomarkers. A 5-ASVs-combination was able to identify controls with a sensitivity of 86%, a specificity of 100%, a negative predictive value of 88%, and a positive predictive value of 100%, while a 7-ASVs-combination was able to recognise with a sensitivity of 90% patients with rejection, ruling out 100% of controls, with a positive predictive value of 100% and a negative predictive value of 91%. Lastly, PICRUSt 2.0 analysis, used to predict metagenomic functions, revealed that the control group was characterised by higher abundance of metabolic genes, including enzymes involved in the bacterial processing of SCFAs, in the electron transport chain and in the heat shock response.Conclusions:Our results lay the foundations for validating promising non-invasive biomarker based on gut bacterial genome to identify patients with AR in a larger cohort of patients. If confirmed, it would have a relevant clinical impact in the field of transplantation. Whether the different bacterial fingerprint between the two groups is a co-cause or consequence of AR remains an open question, which we believe is worth to be clarified through a clinical follow-up study. Lastly, the different predicted functional profiles of the two cohorts are a starting point to further explore the metagenomic profile of gut bacteria of patients with AR.

English

ISBN: 9798342141871Subjects--Topical Terms:

634186
Cancer.

Gut Microbiota as Potential Non-Invasive Biomarker for Kidney Graft Rejection /
LDR:05221nmm a22004573i 4500 001 2437536
005 20251124054801.5
006 m o d
007 cr|nu||||||||
008 261011s2024 miu||||||m |||||||eng d
020 $a 9798342141871
035 $a (MiAaPQD)AAI31604796
035 $a (MiAaPQD)FAUErlangenFAU_31560_
035 $a AAI31604796
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Visconti, Vanessa, $e author. $3 3828554
245 1 0 $a Gut Microbiota as Potential Non-Invasive Biomarker for Kidney Graft Rejection / $c Vanessa Visconti.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (112 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-04, Section: B.
500 $a Advisors: Muller-Deile, J.; Schiffer, M.
502 $b Ph.D. $c Friedrich-Alexander-Universitaet Erlangen-Nuernberg (Germany) $d 2024.
520 $a Background:Kidney graft rejection still represents the major cause of graft loss in kidney transplant recipients. Increasing evidences have demonstrated the link between gut microbiota alterations and allograft outcome, mostly attributable to the bidirectional relationship between gut microbiome and systemic immune system activation's profile. Purpose of this study was to characterize the gut microbiota of kidney transplant recipients with and without allograft rejection (AR) in order to identify a specific microbial fingerprint associated with rejection. We also aimed to define a bacterial genomic biomarker for rejection, which characterisation could lead to the etablishment of a non-invasive method for the diagnosis of AR, thus preventing patient's exposure to possible complications related to renal graft biopsy. Furthermore, we intented to perform a predictional functional analysis in order to hipotetise functional implications of the different microbial compositions between the two groups.Methods:We enrolled a total of 76 patients, of which 66 were suitable for completing the clinical trial. Into this prospective cohort trial involving adult kidney transplant recipients with and without AR, fecal bacterial composition was characterized using 16S rRNA gene sequencing of the V4 hypervariable region, and taxonomy was assigned after amplicon sequence variants (ASV) clustering.Results:Gut microbial composition of recipients with AR was characterised by lower richness, especially pronounced when comparing alpha diversity metrics of patients with cronic active T cellular mediated rejection to controls (Chao1 index p-value= 0.025 and ACE index p-value= 0.02). PERMANOVA analysis based on Aitchison distance, Bray-Curtis dissimilarity and Jaccard distance revealed differences in the microbial beta-diversity between controls and patients with AR with an adjusted p-value respectively of p = 0.01, p=0.021 and p= 0.022. Use of proton pump inhibitors did not significantly influenced the gut microbial composition of the cohorts. We identified a gut microbial fingerprint for each of our study cohorts, where the control group was characterised by a significant enrichment of anti-inflammatory taxa, while the rejection group by bacteria well known for their role in chronic inflammation. We also identified group-specific ASVs able to distinguish patients with AR from controls as non-invasive biomarkers. A 5-ASVs-combination was able to identify controls with a sensitivity of 86%, a specificity of 100%, a negative predictive value of 88%, and a positive predictive value of 100%, while a 7-ASVs-combination was able to recognise with a sensitivity of 90% patients with rejection, ruling out 100% of controls, with a positive predictive value of 100% and a negative predictive value of 91%. Lastly, PICRUSt 2.0 analysis, used to predict metagenomic functions, revealed that the control group was characterised by higher abundance of metabolic genes, including enzymes involved in the bacterial processing of SCFAs, in the electron transport chain and in the heat shock response.Conclusions:Our results lay the foundations for validating promising non-invasive biomarker based on gut bacterial genome to identify patients with AR in a larger cohort of patients. If confirmed, it would have a relevant clinical impact in the field of transplantation. Whether the different bacterial fingerprint between the two groups is a co-cause or consequence of AR remains an open question, which we believe is worth to be clarified through a clinical follow-up study. Lastly, the different predicted functional profiles of the two cohorts are a starting point to further explore the metagenomic profile of gut bacteria of patients with AR.
546 $a English
590 $a School code: 0575
650 4 $a Cancer. $3 634186
650 4 $a Physiology. $3 518431
650 4 $a Infections. $3 1621997
650 4 $a Pathogens. $3 3540520
650 4 $a Transplants & implants. $3 3562683
650 4 $a Salmonella. $3 879055
650 4 $a Disease. $3 705846
650 4 $a Immunology. $3 611031
650 4 $a Bacteria. $3 550366
650 4 $a Fatty acids. $3 897910
650 4 $a Diet. $3 626002
650 4 $a Metabolism. $3 541349
650 4 $a Inflammation. $3 662994
650 4 $a Fermentation. $3 658044
650 4 $a Signal transduction. $3 3546420
650 4 $a Dendritic cells. $3 1001571
650 4 $a Antibiotics. $3 670318
650 4 $a Immune system. $3 689864
650 4 $a Taxonomy. $3 3556303
650 4 $a Biomarkers. $3 2205735
650 4 $a Antigens. $3 700737
650 4 $a Pathogenesis. $3 3561735
650 4 $a Microorganisms. $3 666946
650 4 $a Metabolites. $3 683644
650 4 $a Cellular biology. $3 3172791
650 4 $a Microbiology. $3 536250
650 4 $a Pathology. $3 643180
650 4 $a Pharmaceutical sciences. $3 3173021
650 4 $a Surgery. $3 707153
650 4 $a Medicine. $3 641104
690 $a 0982
690 $a 0719
690 $a 0379
690 $a 0410
690 $a 0571
690 $a 0572
690 $a 0576
690 $a 0564
710 2 $a Friedrich-Alexander-Universitaet Erlangen-Nuernberg (Germany). $e degree granting institution. $3 3822004
720 1 $a Muller-Deile, J. $e degree supervisor.
720 1 $a Schiffer, M. $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-04B.
790 $a 0575
791 $a Ph.D.
792 $a 2024
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31604796